Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Characterizing Sleep Spindles in Sheep.

Schneider WT, Vas S, Nicol AU, Morton AJ.

eNeuro. 2020 Mar 18;7(2). pii: ENEURO.0410-19.2020. doi: 10.1523/ENEURO.0410-19.2020. Print 2020 Mar/Apr.

2.

Acute 5-HT2C Receptor Antagonist SB-242084 Treatment Affects EEG Gamma Band Activity Similarly to Chronic Escitalopram.

Papp N, Koncz S, Kostyalik D, Kitka T, Petschner P, Vas S, Bagdy G.

Front Pharmacol. 2020 Jan 29;10:1636. doi: 10.3389/fphar.2019.01636. eCollection 2019.

3.

AM-251, A Cannabinoid Antagonist, Modifies the Dynamics of Sleep-Wake Cycles in Rats.

Bogáthy E, Papp N, Vas S, Bagdy G, Tóthfalusi L.

Front Pharmacol. 2019 Jul 26;10:831. doi: 10.3389/fphar.2019.00831. eCollection 2019.

4.

Additive effect of 5-HT2C and CB1 receptor blockade on the regulation of sleep-wake cycle.

Bogáthy E, Papp N, Tóthfalusi L, Vas S, Bagdy G.

BMC Neurosci. 2019 Mar 20;20(1):14. doi: 10.1186/s12868-019-0495-7.

5.

Blockade of Serotonin 2C Receptors with SB-242084 Moderates Reduced Locomotor Activity and Rearing by Cannabinoid 1 Receptor Antagonist AM-251.

Bogáthy E, Kostyalik D, Petschner P, Vas S, Bagdy G.

Pharmacology. 2019;103(3-4):151-158. doi: 10.1159/000495939. Epub 2019 Jan 23.

PMID:
30673678
6.

'I would describe myself as a deformed troll': Using interpretative phenomenological analysis to explore body image struggles among palliative care patients.

Vas S, Povey R, Clark-Carter D.

Palliat Med. 2019 Feb;33(2):232-240. doi: 10.1177/0269216318811723. Epub 2018 Nov 12. No abstract available.

PMID:
30415599
7.

Acute and chronic escitalopram alter EEG gamma oscillations differently: relevance to therapeutic effects.

Papp N, Vas S, Bogáthy E, Kátai Z, Kostyalik D, Bagdy G.

Eur J Pharm Sci. 2018 Aug 30;121:347-355. doi: 10.1016/j.ejps.2018.06.012. Epub 2018 Jun 14.

PMID:
29908300
8.

Effects of IL1B single nucleotide polymorphisms on depressive and anxiety symptoms are determined by severity and type of life stress.

Kovacs D, Eszlari N, Petschner P, Pap D, Vas S, Kovacs P, Gonda X, Juhasz G, Bagdy G.

Brain Behav Immun. 2016 Aug;56:96-104. doi: 10.1016/j.bbi.2016.02.012. Epub 2016 Feb 15.

9.

Interleukin-6 promoter polymorphism interacts with pain and life stress influencing depression phenotypes.

Kovacs D, Eszlari N, Petschner P, Pap D, Vas S, Kovacs P, Gonda X, Bagdy G, Juhasz G.

J Neural Transm (Vienna). 2016 May;123(5):541-8. doi: 10.1007/s00702-016-1506-9. Epub 2016 Jan 28.

10.

Exploring the role of neuropeptide S in the regulation of arousal: a functional anatomical study.

Adori C, Barde S, Vas S, Ebner K, Su J, Svensson C, Mathé AA, Singewald N, Reinscheid RR, Uhlén M, Kultima K, Bagdy G, Hökfelt T.

Brain Struct Funct. 2016 Sep;221(7):3521-46. doi: 10.1007/s00429-015-1117-5. Epub 2015 Oct 13.

PMID:
26462664
11.

Chronic escitalopram treatment attenuated the accelerated rapid eye movement sleep transitions after selective rapid eye movement sleep deprivation: a model-based analysis using Markov chains.

Kostyalik D, Vas S, Kátai Z, Kitka T, Gyertyán I, Bagdy G, Tóthfalusi L.

BMC Neurosci. 2014 Nov 19;15:120. doi: 10.1186/s12868-014-0120-8.

12.

Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns.

Bergman P, Adori C, Vas S, Kai-Larsen Y, Sarkanen T, Cederlund A, Agerberth B, Julkunen I, Horvath B, Kostyalik D, Kalmár L, Bagdy G, Huutoniemi A, Partinen M, Hökfelt T.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3735-44. doi: 10.1073/pnas.1412189111. Epub 2014 Aug 18.

13.

A study of bacterial cultures obtained from MR imaging equipment.

Temme JB, Honeycutt K, Vas S.

Radiol Manage. 2014 May-Jun;36(3):22-9; quiz 30-1.

PMID:
25004682
14.

Chronic escitalopram treatment caused dissociative adaptation in serotonin (5-HT) 2C receptor antagonist-induced effects in REM sleep, wake and theta wave activity.

Kostyalik D, Kátai Z, Vas S, Pap D, Petschner P, Molnár E, Gyertyán I, Kalmár L, Tóthfalusi L, Bagdy G.

Exp Brain Res. 2014 Mar;232(3):935-46. doi: 10.1007/s00221-013-3806-8. Epub 2014 Jan 7.

PMID:
24395141
15.

Nesfatin-1/NUCB2 as a potential new element of sleep regulation in rats.

Vas S, Ádori C, Könczöl K, Kátai Z, Pap D, Papp RS, Bagdy G, Palkovits M, Tóth ZE.

PLoS One. 2013;8(4):e59809. doi: 10.1371/journal.pone.0059809. Epub 2013 Apr 1.

16.

Acute escitalopram treatment inhibits REM sleep rebound and activation of MCH-expressing neurons in the lateral hypothalamus after long term selective REM sleep deprivation.

Kátai Z, Adori C, Kitka T, Vas S, Kalmár L, Kostyalik D, Tóthfalusi L, Palkovits M, Bagdy G.

Psychopharmacology (Berl). 2013 Aug;228(3):439-49. doi: 10.1007/s00213-013-3046-4. Epub 2013 Mar 21.

PMID:
23515582
17.

Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment.

Vas S, Kátai Z, Kostyalik D, Pap D, Molnár E, Petschner P, Kalmár L, Bagdy G.

J Neural Transm (Vienna). 2013 Jan;120(1):169-76. doi: 10.1007/s00702-012-0847-2. Epub 2012 Jun 24.

PMID:
22729519
18.

Low ambient temperature reveals distinct mechanisms for MDMA-induced serotonergic toxicity and astroglial Hsp27 heat shock response in rat brain.

Adori C, Andó RD, Balázsa T, Soti C, Vas S, Palkovits M, Kovács GG, Bagdy G.

Neurochem Int. 2011 Oct;59(5):695-705. doi: 10.1016/j.neuint.2011.06.017. Epub 2011 Jul 5.

PMID:
21756954
19.

Association between the activation of MCH and orexin immunorective neurons and REM sleep architecture during REM rebound after a three day long REM deprivation.

Kitka T, Adori C, Katai Z, Vas S, Molnar E, Papp RS, Toth ZE, Bagdy G.

Neurochem Int. 2011 Oct;59(5):686-94. doi: 10.1016/j.neuint.2011.06.015. Epub 2011 Jun 28.

PMID:
21740944
20.

The physician assistant.

Vas S.

Br J Gen Pract. 2010 Nov;60(580):855. doi: 10.3399/bjgp10X539344. No abstract available.

21.

Elevated BDNF protein level in cortex but not in hippocampus of MDMA-treated Dark Agouti rats: a potential link to the long-term recovery of serotonergic axons.

Adori C, Andó RD, Ferrington L, Szekeres M, Vas S, Kelly PA, Hunyady L, Bagdy G.

Neurosci Lett. 2010 Jul 5;478(2):56-60. doi: 10.1016/j.neulet.2010.04.061. Epub 2010 May 8.

PMID:
20435092
22.

Medicinal chemistry of 5-HT5A receptor ligands: a receptor subtype with unique therapeutical potential.

Volk B, Nagy BJ, Vas S, Kostyalik D, Simig G, Bagdy G.

Curr Top Med Chem. 2010;10(5):554-78. Review.

PMID:
20166946
23.

Management of abdominal aortic and iliac artery aneurysms by stent-graft implantation in a patient on CAPD.

Polner K, Gosi G, Vas SI, Kalina I, Acsády G.

Clin Nephrol. 2009 Mar;71(3):359-62.

PMID:
19281754
24.

Improvement in uremic symptoms after increasing daily dialysate volume in patients on chronic peritoneal dialysis with declining renal function.

Liakopoulos V, Krishnan M, Stefanidis I, Savaj S, Ghareeb S, Musso C, Vas S, Bargman JM, Jassal SV, Oreopoulos DG.

Int Urol Nephrol. 2004;36(3):437-43.

PMID:
15783121
25.

Infections related to prosthetic materials in patients on chronic dialysis.

Vas SI.

Minerva Urol Nefrol. 2004 Sep;56(3):259-64. Review.

26.

Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years.

Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Izatt S, Bargman JM, Jassal SV, Vas S, Brunton J, Oreopoulos DG.

Nephrol Dial Transplant. 2004 Dec;19(12):3140-3. Epub 2004 Oct 5.

PMID:
15466881
27.

Differences in survival on peritoneal dialysis between oriental Asians and Caucasians: one center's experience.

Wang T, Tziviskou E, Chu M, Bargman J, Jassal V, Vas S, Oreopoulos DG.

Int Urol Nephrol. 2003;35(2):267-74.

PMID:
15072508
28.

Renal cell carcinoma in peritoneal dialysis patients.

Savaj S, Liakopoulos V, Ghareeb S, Musso C, Sahu K, Bargman JM, Vas SI, Oreopoulos DG.

Int Urol Nephrol. 2003;35(2):263-5.

PMID:
15072507
29.

Peritoneal dialysis in a nursing home: limited survival expectations.

Wang T, Izatt S, Dalglish C, Bargman J, Jassal S, Vas S, Oreopoulos D.

Clin Nephrol. 2003 Nov;60(5):373-4. No abstract available.

PMID:
14640246
30.

Structural changes in silicon rubber peritoneal dialysis catheters in patients using mupirocin at the exit site.

Khandelwal M, Bailey S, Izatt S, Chu M, Vas S, Bargman J, Oreopoulos D.

Int J Artif Organs. 2003 Oct;26(10):913-7.

PMID:
14636007
31.

Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema.

Kalmár L, Bors A, Farkas H, Vas S, Fandl B, Varga L, Füst G, Tordai A.

Hum Mutat. 2003 Dec;22(6):498.

PMID:
14635117
32.

Chiropody may prevent amputations in diabetic patients on peritoneal dialysis.

Lipscombe J, Jassal SV, Bailey S, Bargman JM, Vas S, Oreopoulos DG.

Perit Dial Int. 2003 May-Jun;23(3):255-9.

PMID:
12938826
33.

Peritoneal dialysis in the nursing home.

Wang T, Izatt S, Dalglish C, Jassal SV, Bargman J, Vas S, Tziviskou E, Oreopoulos D.

Int Urol Nephrol. 2002;34(3):405-8.

PMID:
12899237
34.

Mutations in the retinoblastoma-related gene RB2/p130 in adult T-cell leukaemia/lymphoma.

Takeuchi S, Takeuchi N, Tsukasaki K, Fermin AC, De Vas S, Seo H, Koeffler HP.

Leuk Lymphoma. 2003 Apr;44(4):699-701.

PMID:
12769348
35.

Gynecological surgery: not a contraindication for continuation of CAPD.

Bellizzi V, Giannoulias D, Al-Sunaid M, Tziviskou E, Aggarwal HK, Khandelwal M, Bargman JM, Jassal SV, Vas SI, Oreopoulos DG.

Perit Dial Int. 2003 Mar-Apr;23(2):193-6. No abstract available.

PMID:
12713089
36.
37.

Predictors of outcome following bacterial peritonitis in peritoneal dialysis.

Krishnan M, Thodis E, Ikonomopoulos D, Vidgen E, Chu M, Bargman JM, Vas SI, Oreopoulos DG.

Perit Dial Int. 2002 Sep-Oct;22(5):573-81.

PMID:
12455568
38.

Infections related to prosthetic materials in patients on chronic dialysis.

Vas SI.

Clin Microbiol Infect. 2002 Nov;8(11):705-8. Review. No abstract available.

39.

Hypotension in patients on chronic peritoneal dialysis: etiology, management, and outcome.

Malliara M, Passadakis P, Panagoutsos S, Theodoridis M, Thodis E, Bargman J, Jassal V, Vas S, Vargemezis V, Oreopoulos D.

Adv Perit Dial. 2002;18:49-54.

PMID:
12402586
40.

Normal or low initial PTH levels are not a predictor of morbidity/mortality in patients undergoing chronic peritoneal dialysis.

Dimkovic NB, Bargman J, Vas S, Oreopoulos DG.

Perit Dial Int. 2002 Mar-Apr;22(2):204-10.

PMID:
11990405
41.

Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection.

Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, Jassal V, Oreopoulos D.

Perit Dial Int. 2001 Nov-Dec;21(6):554-9.

PMID:
11783763
42.

Local application of mupirocin at the peritoneal catheter exit site prevents early postoperative infections and should become standard practice.

Prakashan KP, Annigeri RA, Chu M, Bargman JM, Vas SI, Oreopoulos DG.

Perit Dial Int. 2001 Sep-Oct;21(5):526-7. No abstract available.

PMID:
11757842
43.

Is catheter function influenced by the side of the body in which the peritoneal dialysis catheter is placed?

de la Cruz MC, Dimkovic N, Bargman JM, Vas SI, Oreopoulos DG.

Perit Dial Int. 2001 Sep-Oct;21(5):526. No abstract available.

PMID:
11757841
44.

Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function.

Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG.

Nephrol Dial Transplant. 2001 Nov;16(11):2207-13.

PMID:
11682669
45.

Chronic peritoneal dialysis in octogenarians.

Dimkovic NB, Prakash S, Roscoe J, Brissenden J, Tam P, Bargman J, Vas SI, Oreopoulos DG.

Nephrol Dial Transplant. 2001 Oct;16(10):2034-40.

PMID:
11572893
46.

Infections in patients undergoing peritoneal dialysis.

Vas S, Oreopoulos DG.

Infect Dis Clin North Am. 2001 Sep;15(3):743-74. Review.

PMID:
11570140
47.

Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.

Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Oreopoulos D.

Perit Dial Int. 2001 May-Jun;21(3):290-5.

PMID:
11475345
48.

Excessive weight gain during peritoneal dialysis.

Jolly S, Chatatalsingh C, Bargman J, Vas S, Chu M, Oreopoulos DG.

Int J Artif Organs. 2001 Apr;24(4):197-202.

PMID:
11394699
49.

Changing picture of peritonitis in peritoneal dialysis.

Vas S.

Am J Kidney Dis. 2000 Nov;36(5):1057-8. No abstract available.

PMID:
11054367
50.

Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it.

Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG.

Perit Dial Int. 2000 Jul-Aug;20(4):429-38.

PMID:
11007375

Supplemental Content

Support Center